Hollon · Nutrients 2015 · Ex-vivo controlled tissue explant study · n=23

Effect of gliadin on permeability of intestinal biopsy explants from celiac disease patients and patients with non-celiac gluten sensitivity.

Cited 216 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Ex-vivo laboratory experiment using human duodenal biopsy explants

PubMed 25734566 · doi:10.3390/nu7031565 · record verified 2026-08-26

What was done

Human duodenal biopsy explants were obtained from four groups: active celiac disease (ACD, n = 6), celiac disease in remission (RCD, n = 6), non-celiac gluten sensitivity (GS, n = 6), and non-celiac controls (NC, n = 5). Biopsies were mounted in microsnapwells and incubated luminally with either gliadin or media alone. Transepithelial electrical resistance was monitored over 120 minutes to assess permeability, and cytokines in the media were quantified.

What was found

Gliadin exposure increased permeability compared to media alone across all four groups. The increase in permeability in ACD was greater than in RCD and NC. The increase in permeability in GS was greater than in RCD. No significant differences in permeability were observed between ACD and GS, RCD and NC, or NC and GS. IL-10 levels in the media were significantly greater in the NC group compared to the RCD and GS groups. Exact numerical values and effect sizes were not reported in the abstract.

Why it matters

This study provides ex-vivo evidence that gliadin can alter epithelial barrier integrity in both healthy individuals and patients with gluten-related disorders, with heightened permeability responses in active celiac disease and gluten sensitivity.

Limits

The sample size is very small (N = 23 across four groups). The ex-vivo design lacks whole-body physiological context, immune interactions, and digestive factors. No quantitative values, variances, or exact p-values were provided in the abstract.

Cited by